Literature DB >> 8629392

Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies.

G Sauter1, G Feichter, J Torhorst, H Moch, H Novotna, U Wagner, U Dürmüller, F M Waldman.   

Abstract

OBJECTIVE: To evaluate the feasibility of erbB-2 amplification analysis of fine needle aspiration (FNA) biopsies. STUDY
DESIGN: FNA smears and dissociated nuclei from 58 breast cancer samples were examined by dual-labeling fluorescence in situ hybridization (FISH) with probes for centromere 17 and the erbB-2 gene. The results were compared with the outcome of erbB-2 immunohistochemistry.
RESULTS: Tumors were categorized according to the erbB-2/centromere 17 signal ratio. There were 23 tumors with high-level amplification, four cases with a low-level erbB-2 gain and 27 tumors with normal erbB-2 content. Four tumors showed an erbB-2 deletion, all in patients < or = 42 years of age. ErbB-2 amplification was strongly associated with positive erbB-2 immunostaining (P < .0001). Comparison of FISH analysis on dissociated cells and on FNA biopsies showed high correspondence (P < .0001).
CONCLUSION: FISH allows reliable detection of erbB-2 gene amplification on FNA biopsies.

Entities:  

Mesh:

Year:  1996        PMID: 8629392     DOI: 10.1159/000333683

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  8 in total

1.  Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma.

Authors:  Andreas Zettl; German Ott; Angela Makulik; Tiemo Katzenberger; Petr Starostik; Thorsten Eichler; Bernhard Puppe; Martin Bentz; Hans Konrad Müller-Hermelink; Andreas Chott
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Significance of immunohistochemical c-ErbB-2 product localisation pattern for prognosis in human breast cancer.

Authors:  S A Aziz; S Pervez; S Khan; N Kayani; S I Azam; M H Rahbar
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  Recurrent genetic aberrations in thymoma and thymic carcinoma.

Authors:  A Zettl; P Ströbel; K Wagner; T Katzenberger; G Ott; A Rosenwald; K Peters; A Krein; M Semik; H K Müller-Hermelink; A Marx
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

4.  Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates.

Authors:  D T McManus; A H Patterson; P Maxwell; M W Humphreys; N H Anderson
Journal:  Mol Pathol       Date:  1999-04

5.  Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma.

Authors:  C Lavarino; V Corletto; A Mezzelani; G Della Torre; C Bartoli; C Riva; M A Pierotti; F Rilke; S Pilotti
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

6.  c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.

Authors:  A Mezzelani; L Alasio; C Bartoli; M G Bonora; M A Pierotti; F Rilke; S Pilotti
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

7.  Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics.

Authors:  H Engel; C Kleespies; J Friedrich; M Breidenbach; A Kallenborn; T Schöndorf; H Kolhagen; P Mallmann
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

8.  HER2 gene status in primary breast cancers and matched distant metastases.

Authors:  Coya Tapia; Spasenija Savic; Urs Wagner; René Schönegg; Hedvika Novotny; Bruno Grilli; Michelle Herzog; Audrey Devito Barascud; Inti Zlobec; Gieri Cathomas; Luigi Terracciano; Georg Feichter; Lukas Bubendorf
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.